Statement on ayahuasca.
Int J Drug Policy March 27, 2012 Brian T. Anderson, Beatriz C. Labate, Matthew Meyer et al. 26 citations
No Summary
Int J Drug Policy
ISSN 0955-3959; 1873-4758;
3 papers in the library · 29 citations · publishing 2012-2025
Papers
Difficulties following naturalistic psychedelic use and associations with adverse childhood experiences.
Int J Drug Policy December 13, 2025 Michelle Olofsson, Walter Osika, Simon B. Goldberg et al. 2 citations
A cross-sectional survey of 3,168 U.S. adults with lifetime psychedelic use found that most (87.9%) reported no difficulties. Among those who did, 6.4% experienced post-acute difficulties lasting more than one day, and 1.3% for more than one year. The most common difficulties were general anxiety, negative changes in self-concept, and social disconnection. Childhood adversity was associated with higher odds of psychedelic-related difficulties: individuals with 2, 3, or 4 or more adverse childhood experiences had roughly double to nearly triple the odds of difficulties compared to those with none. Those with 4 or more ACEs also had higher odds of difficulties persisting beyond one day or one week.
Taking the potential harms of psychedelic-assisted therapy seriously: How do we prevent or mitigate the risks to vulnerable patients?
Int J Drug Policy July 26, 2024 Sharon R. Sznitman, Barbara Broers, Reto Auer et al. 1 citation
The article argues that the potential harms of psychedelic-assisted therapy must be taken seriously, focusing on how to prevent or mitigate risks to vulnerable patients. It discusses the need for robust safety protocols, clinical safeguards, and best practices to protect patient well-being. The authors emphasize that without careful risk management and harm reduction strategies, vulnerable individuals may face adverse outcomes. The work calls for integrating patient protection measures into therapeutic protocols and treatment standards to ensure safe clinical practice in psychedelic medicine.